

Elaine Kingwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3332309/publications.pdf>

Version: 2024-02-01

70
papers

2,980
citations

186265

28
h-index

168389

53
g-index

70
all docs

70
docs citations

70
times ranked

3834
citing authors

#	ARTICLE	IF	CITATIONS
1	Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada. <i>Multiple Sclerosis Journal</i> , 2022, 28, 309-322.	3.0	4
2	Disease-modifying drugs for multiple sclerosis and subsequent health service use. <i>Multiple Sclerosis Journal</i> , 2022, 28, 583-596.	3.0	6
3	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	11
4	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	3.0	14
5	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 239-249.	3.0	5
6	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , 2021, 27, 290-302.	3.0	33
7	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 131-140.	2.8	11
8	Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. <i>American Journal of Epidemiology</i> , 2021, 190, 908-917.	3.4	6
9	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 481-487.	2.4	2
10	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e043930.	1.9	9
11	A multiple sclerosis disease progression measure based on cumulative disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852098863.	3.0	3
12	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	4.8	4
13	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1560-1568.	3.0	8
14	Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1510-1518.	3.0	18
15	Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. <i>Drugs and Aging</i> , 2020, 37, 225-235.	2.7	12
16	Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study. <i>Neuroepidemiology</i> , 2020, 54, 131-139.	2.3	22
17	Alemtuzumab and prescription medication use in the MS population. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102086.	2.0	1
18	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 799-819.	2.8	26

#	ARTICLE	IF	CITATIONS
19	Multiple cause of death analysis in multiple sclerosis. <i>Neurology</i> , 2020, 94, e820-e829.	1.1	25
20	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , 2020, 54, 140-147.	2.3	9
21	Predicting risk of secondary progression in multiple sclerosis: A nomogram. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1102-1112.	3.0	53
22	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1092-1101.	3.0	66
23	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 42-49.	2.0	5
24	Multiple sclerosis: effect of beta interferon treatment on survival. <i>Brain</i> , 2019, 142, 1324-1333.	7.6	34
25	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. <i>Neurology</i> , 2019, 92, e1624-e1633.	1.1	23
26	Socioeconomic status and disability progression in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1497-e1506.	1.1	45
27	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 138-144.	2.0	4
28	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 364-369.	2.0	20
29	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e419-e427.	1.1	67
30	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1050-1056.	1.9	80
31	WED 167â€¦Socioeconomic status and progression of disability in ms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A21.1-A21.	1.9	0
32	Does Molimina Indicate Ovulation? Prospective Data in a Hormonally Documented Single-Cycle in Spontaneously Menstruating Women. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1016.	2.6	8
33	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 57-60.	2.0	8
34	Common variation near IRF6 is associated with IFN- γ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	21.4	32
35	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 232-240.	2.0	18
36	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 258-264.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1506-1516.	3.0	76
38	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 445-451.	10.2	105
39	Evaluating the safety of β -interferons in MS. <i>Neurology</i> , 2017, 88, 2310-2320.	1.1	45
40	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1938-1946.	3.0	107
41	Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll. <i>Scientific Reports</i> , 2017, 7, 3432.	3.3	34
42	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , 2017, 7, e016276.	1.9	2
43	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 702-711.	1.9	27
44	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e018612.	1.9	4
45	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. <i>International Journal of Population Data Science</i> , 2017, 1, 28.	0.1	0
46	Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1150-1159.	1.9	4
47	Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 453-453.	1.9	5
48	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 78-85.	2.0	53
49	Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. <i>American Journal of Epidemiology</i> , 2016, 184, 325-335.	3.4	68
50	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1287-1295.	1.1	79
51	Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	40
52	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). <i>Journal of Neurology</i> , 2015, 262, 2352-2363.	3.6	100
53	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1305-1317.	2.4	8
54	Assessment of cancer risk with β -interferon treatment for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1096-1102.	1.9	29

#	ARTICLE	IF	CITATIONS
55	Marginal Structural Cox Models for Estimating the Association Between \hat{I}^2 -Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. <i>American Journal of Epidemiology</i> , 2014, 180, 160-171.	3.4	61
56	Association between beta-interferon exposure and hospital events in multiple sclerosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1213-1222.	1.9	9
57	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , 2013, 13, 128.	1.8	392
58	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. <i>Neuroepidemiology</i> , 2013, 40, 195-210.	2.3	169
59	Interferon Beta and Long-term Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 651.	9.0	4
60	Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). <i>Multiple Sclerosis Journal</i> , 2012, 18, 442-450.	3.0	50
61	Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 247-56.	7.4	234
62	Cancer risk in multiple sclerosis: findings from British Columbia, Canada. <i>Brain</i> , 2012, 135, 2973-2979.	7.6	82
63	Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. <i>Clinical Therapeutics</i> , 2012, 34, 341-350.	2.5	36
64	Hospital admissions and MS: temporal trends and patient characteristics. <i>American Journal of Managed Care</i> , 2012, 18, 735-42.	1.1	24
65	The natural history of secondary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1039-1043.	1.9	191
66	Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. <i>Journal of the Neurological Sciences</i> , 2010, 292, 57-62.	0.6	37
67	Interferons and multiple sclerosis: is it plausible that \hat{I}^2 -IFN treatment could influence the risk of cancer among MS patients?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1263-1265.	2.8	8
68	The natural history of primary progressive multiple sclerosis. <i>Neurology</i> , 2009, 73, 1996-2002.	1.1	156
69	Perimenopausal Bone Loss: More than Estrogen Depletion. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 2365-2366.	2.8	1
70	Language and Behavior in Children with Sotos Syndrome. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1994, 33, 1307-1315.	0.5	42